VRTX — Patent Expiration for TRIKAFTA (COPACKAGED) - US12214083
Feb 27, 2033, 12:00:00 AM UTC
Summary
The U.S. Patent US12214083, expiring on February 27, 2033, pertains to TRIKAFTA (COPACKAGED), a drug developed by Vertex Pharmaceuticals Inc. The patent covers pharmaceutical compositions aimed at treating cystic fibrosis, specifically involving solid dispersions of a key compound. The expiration of this patent may open the market to generic competitors, potentially impacting Vertex's revenue from TRIKAFTA, which has been a significant product for the company.
Company
VERTEX PHARMACEUTICALS INC (VRTX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.vrtx.comSimilar Events
Patent US8324242 Expiry for TRIKAFTA (COPACKAGED)
The US patent US8324242, assigned to Vertex Pharmaceuticals Inc, related to TRIKAFTA (COPACKAGED), is set to expire on August 5, 2027. TRIKAFTA is an important treatment for cystic fibrosis, utilizing modulators of ATP-Binding Cassette transporters, including the Cystic Fibrosis Transmembrane Conductance Regulator. The expiration of this patent could potentially allow for generic alternatives to enter the market, affecting Vertex Pharmaceuticals' revenues from this product.
Patent ExpirationPatent US8598181 Expiration for TRIKAFTA
Patent US8598181 related to Vertex Pharmaceuticals Inc's product TRIKAFTA is set to expire on May 1, 2027. This expiration could significantly impact TRIKAFTA's market exclusivity in the treatment of cystic fibrosis, potentially altering the competitive landscape for this therapy. The patent concerns compounds that modulate ATP-Binding Cassette transporters, including Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), and methods for treating diseases associated with these transporters.
Patent ExpirationPatent Expiration for TRIKAFTA Product
Vertex Pharmaceuticals Inc's patent (US9012496) for its TRIKAFTA product, designed for the treatment of cystic fibrosis, is set to expire on July 15, 2033. The patent covers a pharmaceutical composition comprising a key compound that aids in the treatment of CFTR-mediated diseases. The expiration may open the market to generic competition, potentially impacting Vertex's revenues derived from this critical product.
Patent ExpirationPatent US8415387 Expiration Date for TRIKAFTA
The patent US8415387 related to the drug TRIKAFTA, developed by Vertex Pharmaceuticals Inc, is set to expire on November 12, 2027. TRIKAFTA is a combination drug designed to treat cystic fibrosis by modulating ATP-Binding Cassette transporters. The expiration of this patent may expose the market to generic alternatives, potentially impacting Vertex's market exclusivity and revenue from the product significantly.
patent expiration